XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.…
XTL Biopharmaceuticals (NASDAQ: XTLB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 1.370 USD on 20 November 2026, down 63.6% over 52 weeks. Its 52-week range is 1.370 USD to 5.640 USD, and it trades at the bottom of that range.
Its market capitalisation is 3.37M USD.
XTL Biopharmaceuticals reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 76.00K USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.